These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
759 related items for PubMed ID: 22370315
1. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. Koppelmans V, Breteler MM, Boogerd W, Seynaeve C, Gundy C, Schagen SB. J Clin Oncol; 2012 Apr 01; 30(10):1080-6. PubMed ID: 22370315 [Abstract] [Full Text] [Related]
2. Late effects of adjuvant chemotherapy for breast cancer on fine motor function. Hoogendam YY, Schagen SB, Ikram MA, Boogerd W, Seynaeve C, Seidler RD, Breteler MM, Van der Geest JN, Koppelmans V. Psychooncology; 2015 Dec 01; 24(12):1799-807. PubMed ID: 25756497 [Abstract] [Full Text] [Related]
3. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial. Watanabe T, Sano M, Takashima S, Kitaya T, Tokuda Y, Yoshimoto M, Kohno N, Nakagami K, Iwata H, Shimozuma K, Sonoo H, Tsuda H, Sakamoto G, Ohashi Y. J Clin Oncol; 2009 Mar 20; 27(9):1368-74. PubMed ID: 19204202 [Abstract] [Full Text] [Related]
4. Incidental findings on brain Magnetic Resonance Imaging in long-term survivors of breast cancer treated with adjuvant chemotherapy. Koppelmans V, Schagen SB, Poels MM, Boogerd W, Seynaeve C, van der Lugt A, Breteler MM. Eur J Cancer; 2011 Nov 20; 47(17):2531-6. PubMed ID: 21745734 [Abstract] [Full Text] [Related]
5. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA. J Clin Exp Neuropsychol; 2004 Oct 20; 26(7):955-69. PubMed ID: 15742545 [Abstract] [Full Text] [Related]
6. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B. Weiss RB, Woolf SH, Demakos E, Holland JF, Berry DA, Falkson G, Cirrincione CT, Robbins A, Bothun S, Henderson IC, Norton L, Cancer and Leukemia Group B. J Clin Oncol; 2003 May 01; 21(9):1825-35. PubMed ID: 12721260 [Abstract] [Full Text] [Related]
7. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma. Cocconi G, Di Blasio B, Boni C, Bisagni G, Ceci G, Rondini E, Bella M, Leonardi F, Savoldi L, Camisa R, Bruzzi P. Cancer; 2002 Jul 15; 95(2):228-35. PubMed ID: 12124820 [Abstract] [Full Text] [Related]
8. Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy. Kreukels BP, Schagen SB, Ridderinkhof KR, Boogerd W, Hamburger HL, van Dam FS. Breast Cancer Res Treat; 2005 Nov 15; 94(1):53-61. PubMed ID: 16175317 [Abstract] [Full Text] [Related]
9. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89. Ejlertsen B, Mouridsen HT, Jensen MB. Acta Oncol; 2008 Nov 15; 47(4):662-71. PubMed ID: 18465334 [Abstract] [Full Text] [Related]
10. [Results of a study on fatigue in breast cancer patients receiving adjuvant chemotherapy: the first four days after treatment are the worst]. de Jong N, Kester AD, Schouten HC, Abu-Saad HH, Courtens AM. Pflege Z; 2007 Nov 15; 60(11):620-5. PubMed ID: 18062627 [Abstract] [Full Text] [Related]
11. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate). Schmid P, Untch M, Wallwiener D, Kossé V, Bondar G, Vassiljev L, Tarutinov V, Kienle E, Lüftner D, Possinger K, TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate). Anticancer Res; 2002 Nov 15; 22(4):2325-32. PubMed ID: 12174922 [Abstract] [Full Text] [Related]
12. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. Leonard RC, Lind M, Twelves C, Coleman R, van Belle S, Wilson C, Ledermann J, Kennedy I, Barrett-Lee P, Perren T, Verrill M, Cameron D, Foster E, Yellowlees A, Crown J, Anglo-Celtic Cooperative Oncology Group. J Natl Cancer Inst; 2004 Jul 21; 96(14):1076-83. PubMed ID: 15265969 [Abstract] [Full Text] [Related]
13. Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study. Debess J, Riis JØ, Engebjerg MC, Ewertz M. Breast Cancer Res Treat; 2010 May 21; 121(1):91-100. PubMed ID: 20306129 [Abstract] [Full Text] [Related]
14. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897. Ganz PA, Hussey MA, Moinpour CM, Unger JM, Hutchins LF, Dakhil SR, Giguere JK, Goodwin JW, Martino S, Albain KS. J Clin Oncol; 2008 Mar 10; 26(8):1223-30. PubMed ID: 18227530 [Abstract] [Full Text] [Related]
15. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII. Bernhard J, Zahrieh D, Castiglione-Gertsch M, Hürny C, Gelber RD, Forbes JF, Murray E, Collins J, Aebi S, Thürlimann B, Price KN, Goldhirsch A, Coates AS, International Breast Cancer Study Group Trial VIII. J Clin Oncol; 2007 Jan 20; 25(3):263-70. PubMed ID: 17159194 [Abstract] [Full Text] [Related]
16. Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Partridge A, Gelber S, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Winer E. Eur J Cancer; 2007 Jul 20; 43(11):1646-53. PubMed ID: 17512721 [Abstract] [Full Text] [Related]
17. Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy. Dubsky P, Sevelda P, Jakesz R, Hausmaninger H, Samonigg H, Seifert M, Denison U, Mlineritsch B, Steger G, Kwasny W, Stöger H, Bartsch R, Stierer M, Taucher S, Fridrik M, Schippinger W, Greil R, Pötter R, Gnant M, Austrian Breast and Colorectal Cancer Study Group. Clin Cancer Res; 2008 Apr 01; 14(7):2082-7. PubMed ID: 18381948 [Abstract] [Full Text] [Related]
18. Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer. Ejlertsen B, Mouridsen HT, Jensen MB, Andersen J, Andersson M, Kamby C, Knoop AS, Danish Breast Cancer Cooperative Group. Cancer; 2010 May 01; 116(9):2081-9. PubMed ID: 20186830 [Abstract] [Full Text] [Related]
19. DBCG trial 89B comparing adjuvant CMF and ovarian ablation: similar outcome for eligible but non-enrolled and randomized breast cancer patients. Ejlertsen B, Jensen MB, Mouridsen HT, Andersen J, Cold S, Jakobsen E, Kamby C, Sørensen PG, Ewertz M. Acta Oncol; 2008 May 01; 47(4):709-17. PubMed ID: 18465339 [Abstract] [Full Text] [Related]
20. Long-term quality of life in premenopausal women with node-negative localized breast cancer treated with or without adjuvant chemotherapy. Joly F, Espié M, Marty M, Héron JF, Henry-Amar M. Br J Cancer; 2000 Sep 01; 83(5):577-82. PubMed ID: 10944595 [Abstract] [Full Text] [Related] Page: [Next] [New Search]